Immunotherapy drug used as 1st-line therapy for Merkel cell carcinoma improved survival

(Louisiana State University Health Sciences Center) A multi-center phase II clinical trial investigating pembrolizumab as a first-line and programmed cell death-1 therapy in patients with advanced Merkel cell carcinoma reports lasting tumor control, generally manageable side effects and improved overall survival. Dr. Adam Riker led the study at LSU Health New Orleans.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news